Intermediate risk Myelofibrosis

DrugDrug NameDrug Description
DB11763MomelotinibA Janus Kinase inhibitor used to treat intermediate or high-risk myelofibrosis.
DB08877RuxolitinibA kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
DrugDrug NamePhaseStatusCount